To Read Full News Article Page Down

TRUTH MATTERS Share On Facebook and Twitter

 

The United States Government will convene a workshop focused on development of medical countermeasures against Marburg virus (MARV) and Sudan ebolavirus (SUDV).

 

The recent case of Marburg in Guinea underscores the need for vaccines against these threats. As we work towards product development, it’s important that we try to maximize coordination across programs to avoid duplicative efforts.

icon clipboard task list

PRIMARY EVENT OBJECTIVES

1. Provide consolidated updates of assay/model statuses to product sponsors
2. Create a forum for product sponsors to discuss their assay/model strategies
3. Foster cross-talk & collaboration among product sponsors & assay/model developers

icon several people in linked circleALL STAKEHOLDERS INVITED

Companies, USG interagency partners, and others interested in the topic area are encouraged to attend the January 26, 2022 virtual workshop. The event is open to the public, but space is limited. Be sure to register by January 21, 2022.

 

 

 

CBRN VACCINE MEDICAL COUNTERMEASURES PROGRAM

Expanding our vaccine portfolio to protect against high-consequence biological threats.Vaccine Icon

Support Ebola Outbreak Map . Com Subscribe $5 - $100

CBRN VACCINE MEDICAL COUNTERMEASURES OVERVIEW

Biological threats, whether naturally occurring or intentionally engineered, pose serious threats for which we must be prepared. Vaccines can and will be a major component of response efforts for public health emergencies like smallpox, anthrax, and viral hemorrhagic fevers.

The CBRN Vaccines Program continues to support late-stage development and licensure of programs addressing key high-consequence biological threats. In parallel, we are investing in earlier stage candidates for the next generation of threats. Our goal is to expand our level of preparedness and ensure safe and effective vaccines are ready and stockpiled as part of a comprehensive response to future threats.

Hear directly from Dr. Adam Clark about CBRN Vaccine Program 2022 priorities.
BARDA Industry Day 2021

Adam Clark, Health Scientist with the CBRN Vaccines Program
Pre-recorded for November 3, 2021

 Download Video Transcript

2022 FILOVIRUS VACCINE DEVELOPMENT WORKSHOP

Join BARDA at the virtual Filovirus Vaccine Workshop on January 26, 2022 from 10:00 am to 5:00 pm Eastern.

The United States Government (USG) will convene a workshop focused on development of medical countermeasures against Marburg virus (MARV) and Sudan ebolavirus (SUDV). The recent case of MARV in Guinea underscores the need for vaccines against these threats. As we work towards product development, it’s important that we try to maximize coordination across programs to avoid duplicative efforts.

icon clipboard task list

PRIMARY EVENT OBJECTIVES

1. Provide consolidated updates of assay/model statuses to product sponsors
2. Create a forum for product sponsors to discuss their assay/model strategies
3. Foster cross-talk & collaboration among product sponsors & assay/model developers

icon several people in linked circleALL STAKEHOLDERS INVITED

Companies, USG interagency partners, and others interested in the topic area are encouraged to attend the January 26, 2022 virtual workshop. The event is open to the public, but space is limited. Be sure to register by January 21, 2022.

Thank you for your interest; however, event registration is closed.

CBRN VACCINE INVESTMENT AREAS

Select Investment Area to Learn more

FILOVIRUS VACCINES

ebola

Ebola viruses and Marburg viruses are members of the filovirus family that cause highly lethal viral hemorrhagic fevers. The 2014-2016 Ebola outbreak in West Africa resulted in major investments to push a vaccine against Ebola Zaire to licensure, and this vaccine is now being used as part of ongoing outbreak responses. However, unlike Zaire ebolavirus, we currently do not have licensed vaccines against Marburg virus or Sudan ebolavirus if an outbreak of those species were to occur.

BARDA has several near and long-term requirements in the filovirus vaccine space.

  • Zaire Ebolavirus: We continue to work with our industry partners to ensure an initial inventory of vaccine and to support a second candidate through licensure. Studies are also underway to expand the potential use of these vaccines to special populations and to improve the current cold-chain requirements.
  • Sudan ebolavirus and Marburg virus: Vaccine to protect against these threats are earlier in the pipeline.
    • Our near-term goals for these programs are to establish a pipeline of vaccine candidates and to evaluate these programs in clinical stages of development.
    • Our primary focus is on monovalent candidates that are likely to be effective as single dose vaccines.
    • Given the sporadic nature of outbreaks, mass vaccination campaigns may not be feasible, so vaccines may be utilized as part of a response effort.
    • Single dose vaccines with rapid onset to protection would be of high utility to slow the spread of outbreaks byvaccinating healthcare workers, frontline responders, and high-risk contacts.

 

ANTHRAX VACCINES

Anthrax Vaccine

Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis, which can cause human disease via gastrointestinal, cutaneous, or inhalational (pulmonary) routes. Clinical manifestations of the disease differ by route and inhalational anthrax is the most lethal. Biothrax is currently licensed for use as pre- and post-exposure prophylaxis (post-exposure in combination with antibiotics).

BARDA’s Anthrax Vaccine Strategy has two major components:

  1. Continue pushing a next-generation vaccine, AV7909, to licensure as a two-dose post-exposure prophylaxis. This will reduce the number of doses required for protection as well as the time to onset of protection.
  2. Invest in solutions that improve the operational logistics of the current lead vaccines. This will involve clinical development to support use in special populations and to extend the usable shelf life of vaccines.

Future Investments Opportunities:

  • While these efforts are focused on licensed products and those nearing licensure, we continue to work with our interagency partners to evaluate earlier stage anthrax vaccine programs.

We are interested in innovative approaches and technologies that may enable protection with a single dose and remove some of the downstream bottlenecks of distribution and administration.

SMALLPOX VACCINES

Countermeasures Smallpox

Smallpox is a highly lethal disease that was eradicated over 40 years ago. However, we must maintain a high level of preparedness against this disease given how easily it could spread if ever re-introduced. Importantly, advances in synthetic biology have potential to make the re-introduction of smallpox more feasible.

We continue to foster a level of preparedness by improving on the current baseline. We have licensed vaccines, one of which can be used in special populations such as older adults and immune-compromised individuals. We will continue to pursue efforts to improve the operational use of the licensed vaccines. The Vaccine Program will also work towards a lyophilized formulation to create a product with a much longer shelf-life, greatly enhancing the financial sustainability of the program.

 

VACCINES TO COUNTER MULTI-DRUG RESISTANT (MDR) THREATS

Vaccines to Counter Multi-Drug Resistant (MDR) Threats

These four pathogens are among the top public health threats because of their cost, incidence, morbidity and mortality, and their overlap with other public health emergencies. AMR can hinder emergency response by worsening outcomes, regardless of root cause.

Learn more by visiting our Partnering on Vaccines to Counter Multi-Drug Resistant (MDR)  where we outline how we can work together to develop a vaccine against MDR Vaccines.

 

INNOVATING BEYOND THE NEEDLE

BTN Logo

The CBRN Vaccine and DRIVe teams are partnered together to support alternative delivery platforms that transform vaccination and other drug delivery by bringing new technologies into the marketplace.

The Beyond the Needle initiative is developing alternative technologies that aim to transform the paradigm by making vaccines easier to administer and more widely available without the need for needles, syringes, vials, and cold-chain distribution burdens. The CBRN Vaccine team wants to take the concept further and revolutionize vaccine production.

In parallel with evaluating needle-free approaches, the team is seeking to use 3D printing or related technologies that may enable distributed, on-demand vaccine manufacturing. Distributed manufacturing may be a key to reducing or removing some of the downstream bottlenecks associated with manufacturing scale up and distribution.

 

CBRN has a proven track record of developing life-saving medical countermeasures. We will continue to work with partners old and new to treat or prevent the medical consequences that result from CBRN threats.

Evaluation of BioThrax® and AV7909 Anthrax Vaccines in Adults 66 Years of Age or Older


TRUTH MATTERS Share On Facebook and Twitter

Leave a Reply

Ebola Outbreak Map ®

Ebola Outbreak Map®

TRADEMARK REGISTRATION # 4759271

Ebola Outbreak Map registered trademark is for sale.

Imagine the possibilities of having exclusive rights for an Ebola Map.

Ebola United States

Ebola Outbreak Map® registered trademark and the website Ebola Outbreak Map is now for sale to all interested parties.

Ebola Outbreak Map . Com website tracks Ebola and locations with Ebola Monitoring. https://www.ebolaoutbreakmap.com/

Ebola Outbreak Map inputs Ebola locations onto a map that is viewable by people worldwide on Ebola Outbreak Map . Com.

Ebola Outbreak Map is trademarked no other company or corporation may have an Ebola Map.

Violation of trademark law is very serious.

Ebola Outbreak Map® is registered under the Federal Trademark Act of 1946 with the United States Patent and Trademark Office.

Any unauthorized use, publication or infringement of this designation without express written permission is prohibited.

Such violation is subject to liability for damages, injunctive relief, attorney’s fees and other penalties, civil and criminal.

Ebola Outbreak Map®

https://www.ebolaoutbreakmap.com

TRADEMARK REGISTRATION # 4759271

Ebola Outbreak Map registered trademark is for sale.

Imagine the possibilities of having exclusive rights for an Ebola Map.

IC 035. US 100 101 102. G & S: Advertising and directory services, namely, promoting the services of others by providing a web page featuring links to the websites of others; Marketing the goods and services of others by hyperlinking and placing ads on a website; Promoting and marketing the goods and services of others by offering ad space on a website to place ads; Promoting the goods and services of others by offering ad space on a website to place ads; Provision of space on websites for advertising goods and services.

Ebola Outbreak Map Trademark and Licensing can be purchased.

10% finder’s fee will be paid from the total trademark sale amount to anyone who finds a buyer for the trademark Ebola Outbreak Map.

Interested parties may submit their trademark purchase requests via email: support@ebolaoutbreakmap.com

Now On Amazon, Barnes & Noble And Google Books Store